| [July 27, 2011] |
 |
Cannabis Science Releases Operations Guidance On New Medicinal Cannabis Commercialization Deals
DENVER --(Business Wire)--
Cannabis Science, Inc. (OTCBB: CBIS), a US biotech company developing
pharmaceutical cannabis products, is pleased to provide investor
guidance on its previously announced Medicinal Cannabis
Commercialization negotiations and current operational structures.
Currently, Cannabis Science has some outstanding business opportunities
in the final stages of closing. It anticipates announcing the first one
within the next week. Some of these new deals are designed to bring its
anti-cancer cannabis formulations and its other critical ailment
formulations to the public through the FDA in the USA and more rapidly
through other expanded markets around the world.
One of the larger deals the company expects to sign and announce within
the next few days is a business relationship with a multi-million dollar
pharmaceutical technology provider. Under the terms of the agreement,
Cannabis Science will work closely with the technology provider to
market and sell their co-branded products on an exclusive and
non-exclusive basis with this new ground breaking technology in the
Medical Cannabis industry. Cannabis Science sees this as an incredible
opportunity to participate in an exciting growing technology company
while at the same time advancing its medical marijuana medicine market
and development.
The Company is in advanced stages of negotiations to contract for a
joint-marketing pogram that will provide cancer patients with
proprietary medical marijuana formulations for cancer treatment.
According to the World Health Organization, 12 million cancer deaths are
likely to occur worldwide by 2030. With the $47.7 billion cancer drug
market projected to grow significantly over the coming decades, Cannabis
Science is committed and focused on positioning itself as a key player
in the medical cannabis cancer treatment sector.
Robert Melamede, Ph.D. and Cannabis Science CEO said, "We appreciate the
dedication and patience that many of our investors have shown. We have
been working diligently to provide a path in the complicated legal and
regulatory environment that surrounds the medical cannabis industry that
will benefit our shareholders and the countless people in need around
the world who have been deprived of the health promoting benefits
provided by this unique plant. These commercialization agreements will
give us an opportunity to generate significant revenues for Cannabis
Science We provide a further update and agreement details in the coming
weeks as these commercial agreements are signed."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade
medical marijuana research and development. The Company works with world
authorities on phytocannabinoid science targeting critical illnesses,
and adheres to scientific methodologies to develop, produce and
commercialize phytocannabinoid-based pharmaceutical products. In sum, we
are dedicated to the creation of cannabis-based medicines, both with and
without psychoactive properties, to treat disease and the symptoms of
disease, as well as for general health maintenance.
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Act of 1934. A statement
containing works such as "anticipate," "seek," intend," "believe,"
"plan," "estimate," "expect," "project," "plan," or similar phrases may
be deemed "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events or
results anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include the
future U.S. and global economies, the impact of competition, and the
Company's reliance on existing regulations regarding the use and
development of cannabis-based drugs. Cannabis Science, Inc. does not
undertake any duty nor does it intend to update the results of these
forward-looking statements.

[ Back To TMCnet.com's Homepage ]
|